MS-ResearchBiomarkerS

ConditionsMultiple Sclerosis Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progressive Clinically Isolated Syndrome Radiologically Isolated Syndrome Neuromyelitis Optica Spectrum Disorders Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease Neurologic Autoimmune Disease Neurologic Disorder Healthy Aging

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorCedars-Sinai Medical Center

About this trial

This study is being conducted to investigate risk factors for disability progression in Multiple Sclerosis and related disorders (MSRD). The primary goal is to assess whether combining information from visual assessment, blood markers, as well as historical and ongoing longitudinal MRIs of the brain, orbit (the part of the skull where eyes are located), and/or spinal cord can predict changes in quantitative disability measures related to MSRD and neurological disease.

Eligibility criteria

Qualifiers

Diagnosis of MS, CIS,or RIS based on the 2017 revised McDonald criteria.

Diagnosis of NMOSD based on the 2015 revised NMOSD consensus diagnostic criteria.

Diagnosis of myelin oligodendrocyte glycoprotein (MOG)-related encephalomyelitis, optic neuritis, or other associated disease.

Diagnosis of neurological disorders other than MSRD.

Disqualifiers

Patients will be excluded from the MRI portions of the study if they have a contraindication to MRI(metallic implantsor foreign bodies, claustrophobia, MRI-incompatible pacemakers, MRI- incompatible prosthetic heart valves).

Patients will be excluded from the MRI portions of the study if they are pregnant, but their demographic, clinical information,and disability measures may still be captured under the study.

Patients will be excluded from the visual assessment portions of the study if they have had any recent ocular surgery (within the past two months), refractive errors of greater than or equal to ±6 diopters or other eye diseases that may affect or confound OCT/OCTA measurements (ex., age-related macular degeneration, advanced geographic atrophy, diabetic retinopathy, glaucoma).

Trial design

Treatments tested in this trial

Not listed

Trial groups

1,000 Participants

are grouped into 5 trial groups

Sponsors and collaborators

Cedars-Sinai Medical Center

Lead sponsor

Source ClinicalTrials.gov